Log in

NYSE:AGN - Allergan Stock Price, Forecast & News

$188.19
-2.41 (-1.26 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
$187.82
Now: $188.19
$190.39
50-Day Range
$185.58
MA: $190.55
$193.85
52-Week Range
$114.27
Now: $188.19
$194.61
Volume3.45 million shs
Average Volume2.30 million shs
Market Capitalization$61.78 billion
P/E RatioN/A
Dividend Yield1.55%
Beta1.64
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP01849010
Phone862-261-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.79 billion
Cash Flow$36.54 per share
Book Value$193.10 per share

Profitability

Net Income$-5,096,400,000.00

Miscellaneous

Employees16,900
Market Cap$61.78 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.


Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Friday, January 24th. Investors of record on Friday, February 14th will be given a dividend of $0.74 per share on Friday, March 13th. This represents a $2.96 annualized dividend and a yield of 1.57%. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its board has approved a stock buyback program on Tuesday, January 29th 2019, which permits the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) posted its quarterly earnings results on Tuesday, November, 5th. The company reported $4.25 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $4.25. The firm had revenue of $4.03 billion for the quarter, compared to analysts' expectations of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. Allergan's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.25 EPS. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

What price target have analysts set for AGN?

20 analysts have issued 1-year price targets for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's share price to reach $176.63 in the next year. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for Allergan.

What is the consensus analysts' recommendation for Allergan?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 17 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Has Allergan been receiving favorable news coverage?

Media headlines about AGN stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Allergan.

Are investors shorting Allergan?

Allergan saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,580,000 shares, an increase of 19.2% from the December 15th total of 12,230,000 shares. Based on an average daily volume of 2,220,000 shares, the short-interest ratio is presently 6.6 days. Approximately 4.5% of the company's stock are sold short. View Allergan's Current Options Chain.

Who are some of Allergan's key competitors?

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

Who are Allergan's major shareholders?

Allergan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.18%), New York State Teachers Retirement System (0.14%), Calamos Advisors LLC (0.11%), Metropolis Capital Ltd (0.06%), Vertex One Asset Management Inc. (0.05%) and Advisors Capital Management LLC (0.04%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

Which major investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Strs Ohio, United Services Automobile Association, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Neville Rodie & Shaw Inc., State of Alaska Department of Revenue and Bowling Portfolio Management LLC. View Insider Buying and Selling for Allergan.

Which major investors are buying Allergan stock?

AGN stock was purchased by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Calamos Advisors LLC, Metropolis Capital Ltd, Vertex One Asset Management Inc., Moon Capital Management LLC, New York State Teachers Retirement System, Modus Advisors LLC and Legacy Private Trust Co.. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $188.19.

How big of a company is Allergan?

Allergan has a market capitalization of $61.78 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

What is Allergan's official website?

The official website for Allergan is http://www.allergan.com/.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


MarketBeat Community Rating for Allergan (NYSE AGN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  1,364 (Vote Outperform)
Underperform Votes:  674 (Vote Underperform)
Total Votes:  2,038
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel